Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Alpha Teknova Inc(TKNO)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for TKNO
10/01/2026: TKNO (3-star) is a STRONG-BUY. BUY for 11 days. Simulated Profits (18.93%). Updated daily EoD!
Alpha Teknova is a specialized supplier of essential cell culture media and buffers, playing a critical role in the biopharmaceutical development process. Its main strength lies in its agile manufacturing, which allows the company to provide customized, ready-to-use reagents to clinical-stage biopharma firms. The primary growth opportunity involves scaling these partnerships into long-term commercial supply agreements as customer drug programs advance. However, the company faces risks related to market-wide volatility in biotech funding, heavy reliance on early-stage customers, and intense competition from larger life science incumbents. The stock may best suit growth-oriented investors with a high risk tolerance who are closely monitoring the company's progress toward achieving sustainable profitability and expanded commercial partnerships.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers growth potential in the bioprocessing space but currently lacks consistent profitability. |
| Momentum investor | Weak fit | The stock has faced significant downward pressure, requiring a strong trend reversal to suit momentum strategies. |
| Value investor | Weak fit | The lack of positive earnings makes standard valuation metrics difficult to apply for traditional value investors. |
| Dividend investor | Weak fit | The company does not pay a dividend and focuses entirely on reinvestment. |
| Low-risk investor | Weak fit | Small-cap biotech suppliers typically carry higher volatility and execution risks. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | As a small-cap stock in the biotech sector, TKNO is prone to significant price swings. |
| Valuation risk | Medium / high | High expectations for future growth have led to valuation sensitivity during market corrections. |
| Competition risk (Diversified Life Science Suppliers) | High | The company must compete against much larger firms with greater pricing power and resources. |
| Business quality | Medium | While the core product is essential, the company is still building its scale and market dominance. |
| Dividend income | Low / none | The company does not generate the surplus cash needed to support dividend payments. |
| Execution risk | Medium / high | Successfully transitioning custom solutions to large-scale commercial manufacturing is operationally complex. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit 94.15% | Avg. Invested days 31 | Today’s Advisory Strong Buy |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 10/01/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 477.83M USD | Price to earnings Ratio - | 1Y Target Price 9 |
Price to earnings Ratio - | 1Y Target Price 9 | ||
Volume (30-day avg) 237.3K shares | Beta 0.73 | 52 Weeks Range 1.91 - 9.48 | Updated Date 10/01/2026 |
52 Weeks Range 1.91 - 9.48 | Updated Date 10/01/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.3 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Cell Culture Media | Standard and custom liquid media solutions for bioprocessing. | Selling the essential ingredients needed to grow cells for drug production. |
| Molecular Biology Reagents | Ready-to-use buffers and chemicals for laboratory research. | Providing standardized, ready-made solutions that save labs time. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE - | Forward PE - | Enterprise Value 489.41M | Price to Sales(TTM) 10.93 |
Enterprise Value 489.41M | Price to Sales(TTM) 10.93 | ||
Enterprise Value to Revenue 11.2 | Enterprise Value to EBITDA -6.23 | Shares Outstanding 53.69M | Shares Floating 10.99M |
Shares Outstanding 53.69M | Shares Floating 10.99M | ||
Percent Insiders 9.31 | Percent Institutions 87.34 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Alpha Teknova Inc
Exchange NASDAQ | Headquarters Hollister, CA, United States | ||
IPO Launch date 2021-06-25 | President, CEO & Director Mr. Stephen Gunstream | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 158 | Website https://www.teknova.com |
Full time employees 158 | Website https://www.teknova.com | ||
Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company' primary products include pre-poured media plates for cell growth and cloning; liquid microbial culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.